Home
Sndl Inc.
SNDL Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
Business
Mar 12 2026
27 min read

SNDL Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

news images

The Company Reports Record Full-Year Income Statement Performance and Cash Generation

EDMONTON, Alberta, March 12, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ: SNDL, CSE: SNDL) (“SNDL” or the “Company”) reported its financial and operational results for the full year and fourth quarter ended December 31, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated.

SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com.

The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Thursday, March 12, 2026. The conference call details can be found below.

MANAGEMENT HIGHLIGHTS

  • Net revenue for the fourth quarter of 2025 was $252.5 million, and $946.4 million for the full year of 2025, representing decrease of (2.0)% and growth of +2.8%, respectively, when compared to the same periods of the previous year. The full year represents a new record for the corporation, driven by strong growth from our combined Cannabis business of +11.4%.

  • Gross profit also reached new records, with $70.2 million in the fourth quarter of 2025, and $258.6 million for the full year, representing growth of +2.1% and +7.6%, respectively, when compared to the same periods of the previous year.

  • Gross margin (1) of 27.8% in the fourth quarter of 2025 and 27.3% for the full year are also new records, representing improvements of +1.1 and +1.2 percentage points, respectively, when compared to the same periods of the previous year.

  • Operating Income of $11.8 million for the fourth quarter of 2025 and $(6.3) million for the full year also represent new records, driven by gross margin progression and SG&A efficiency improvements. Excluding restructuring-related charges, Adjusted Operating Income totaled $12.8 million in the fourth quarter of 2025 and, for the first time in the Company’s history, reached break-even for the full year at $0.1 million.

  • Cash flow was positive by $11.7 million in the fourth quarter of 2025 and $33.9 million for the full year, driven by contributions from operating activities. The full year also benefited from interest payments and proceeds from investments.

  • Free cash flow (1) was positive in the fourth quarter of 2025 at $10.2 million and for the full year at $18.0 million, with full-year results more than doubling the prior year’s record and reflecting continued operating momentum.

“2025 represents another step forward in financial performance and strategic focus for SNDL. We are pleased to report new records across our income statement and free cash flow, while continuing to transform our business to support long-term, sustainable, and profitable growth,” said Zach George, Chief Executive Officer of SNDL. “We are strengthening our performance culture and organizational capabilities, providing a solid foundation as we continue to raise the bar toward our vision of becoming a global leader in our industry.”

Beyond our financial results, during the fourth quarter of 2025 and through the first months of 2026 to date, we continued to advance several key initiatives that further strengthen our foundation for long-term success and shareholder value creation, including:

  • SunStream restructuring progress: As U.S. cannabis rescheduling gains momentum, the restructuring of the Parallel and Skymint investments continues to advance toward completion, with only a limited number of remaining requirements outstanding.

  • Strategic organic investments: Capital expenditures increased from $8.6 million in 2024 to $12.8 million in 2025, including $4.0 million in the fourth quarter. The majority of these investments were directed toward new store openings across our Cannabis and Liquor Retail segments.

  • Acquisition of 1CM retail stores: On January 6, 2026, SNDL announced the completion of the acquisition of five Cost Cannabis retail stores located in Alberta and Saskatchewan from 1CM Inc. (“1CM”). We continue to support the regulatory approval process in Ontario for the remaining 27 stores.

  • Share buybacks: Between December 2025 and March 9, 2026, the Company repurchased 4.3 million common shares for cancellation, bringing the total numbers of shares repurchased since the fourth quarter of 2024 to 15.1 million.

  • Progress towards simplification & focus: With more than $20 million in annualized savings delivered to date, the completion of the third and final phase of the corporate restructuring program, announced in mid-2024 and expected to conclude in the second quarter of 2026, positions the Company to exceed the program’s targeted savings. In addition, we are days away from completing full ERP consolidation, which will further enhance operational visibility and process efficiency.

With $252.2 million of unrestricted cash and no debt as of December 31, 2025, and exposure across the Canadian, U.S., and European markets, we are uniquely positioned to deploy capital into both organic and inorganic opportunities to further enhance our portfolio and accelerate growth. Disciplined capital allocation remains a key priority for our management team in 2026, alongside continued execution on efficiency initiatives and profitability-enhancing actions.

TOTAL COMPANY HIGHLIGHTS

 

Three months ended December 31

 

Year ended December 31

 

($000s)

2025

 

2024

 

% Change

 

2025

 

2024

 

% Change

 

IFRS Financial Measures

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

252,499

 

 

257,679

 

 

-2.0

%

 

946,401

 

 

920,448

 

 

2.8

%

Gross profit

 

70,229

 

 

68,799

 

 

2.1

%

 

258,648

 

 

240,331

 

 

7.6

%

Operating income (loss)

 

11,751

 

 

(76,089

)

 

115.4

%

 

(6,349

)

 

(103,811

)

 

93.9

%

Change in cash and cash equivalents

 

11,662

 

 

(44,617

)

 

126.1

%

 

33,884

 

 

23,318

 

 

45.3

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-IFRS Financial Measures (1)

 

 

 

 

 

 

 

 

 

 

 

 

Gross margin

 

27.8

%

 

26.7

%

 

1.1

pp

 

27.3

%

 

26.1

%

 

1.2

pp

Adjusted operating income (loss)

 

12,801

 

 

(60,472

)

 

121.2

%

 

88

 

 

(86,144

)

 

100.1

%

Free cash flow

 

10,218

 

 

11,625

 

 

-12.1

%

 

17,951

 

 

8,872

 

 

102.3

%

(1)   Gross Margin is a supplementary financial measure calculated by dividing Gross Profit by Net Revenue. Adjusted operating income (loss) and Free Cash Flow are specified financial measures that do not have a standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures reported by other companies. See “Non-IFRS Measures” section below for further information.

BUSINESS SEGMENT HIGHLIGHTS

SNDL operates and reports its business through four segments: Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments. Additionally, a consolidated total for Cannabis is presented, encompassing the combined results of the two Cannabis segments, along with the revenue elimination associated with the Cannabis Operations sales to the provincial boards that are expected to be subsequently repurchased by the Company’s licensed retail subsidiaries for resale. Corporate and Shared Service expenses are reported as “Corporate”.

 

Three months ended December 31

 

Year ended December 31

 

($000s)

2025

 

2024

 

% Change

 

2025

 

2024

 

% Change

 

Net Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Cannabis Retail

 

83,282

 

 

83,170

 

 

0.1

%

 

330,242

 

 

311,689

 

 

6.0

%

Cannabis Operations

 

37,112

 

 

37,092

 

 

0.1

%

 

144,656

 

 

109,470

 

 

32.1

%

Intersegment Eliminations

 

(16,738

)

 

(16,663

)

 

-0.5

%

 

(68,129

)

 

(55,970

)

 

-21.7

%

Total Cannabis

 

103,656

 

 

103,599

 

 

0.1

%

 

406,769

 

 

365,189

 

 

11.4

%

Liquor Retail

 

148,843

 

 

154,080

 

 

-3.4

%

 

539,632

 

 

555,259

 

 

-2.8

%

Investments

 

 

 

 

 

0.0

%

 

 

 

 

 

0.0

%

Total

 

252,499

 

 

257,679

 

 

-2.0

%

 

946,401

 

 

920,448

 

 

2.8

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Income

 

 

 

 

 

 

 

 

 

 

 

 

Cannabis Retail

 

8,003

 

 

(8,997

)

 

189.0

%

 

30,332

 

 

(1,742

)

 

1841.2

%

Cannabis Operations

 

1,874

 

 

4,391

 

 

-57.3

%

 

(1,754

)

 

2,663

 

 

-165.9

%

Total Cannabis

 

9,877

 

 

(4,606

)

 

314.4

%

 

28,578

 

 

921

 

 

3002.9

%

Liquor Retail

 

12,240

 

 

12,325

 

 

-0.7

%

 

36,516

 

 

34,781

 

 

5.0

%

Investments

 

2,434

 

 

(63,724

)

 

103.8

%

 

4,209

 

 

(50,013

)

 

108.4

%

Corporate

 

(12,800

)

 

(20,084

)

 

36.3

%

 

(75,652

)

 

(89,500

)

 

15.5

%

Total

 

11,751

 

 

(76,089

)

 

115.4

%

 

(6,349

)

 

(103,811

)

 

93.9

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted Operating Income

 

 

 

 

 

 

 

 

 

 

 

 

Cannabis Retail

 

8,003

 

 

6,003

 

 

33.3

%

 

30,332

 

 

13,258

 

 

128.8

%

Cannabis Operations

 

2,154

 

 

4,439

 

 

-51.5

%

 

2,454

 

 

3,091

 

 

-20.6

%

Total Cannabis

 

10,157

 

 

10,442

 

 

-2.7

%

 

32,786

 

 

16,349

 

 

100.5

%

Liquor Retail

 

12,240

 

 

12,325

 

 

-0.7

%

 

36,516

 

 

34,781

 

 

5.0

%

Investments

 

2,434

 

 

(63,724

)

 

103.8

%

 

4,209

 

 

(50,013

)

 

108.4

%

Corporate

 

(12,030

)

 

(19,515

)

 

38.4

%

 

(73,423

)

 

(87,261

)

 

15.9

%

Total

 

12,801

 

 

(60,472

)

 

121.2

%

 

88

 

 

(86,144

)

 

100.1

%


Liquor Retail

SNDL is Canada's largest private sector liquor retailer, operating at March 11, 2026 in 167 locations, predominantly in Alberta, under its three retail banners: “Wine and Beyond” (15), “Liquor Depot” (19), and “Ace Liquor” (133).

 

Three months ended December 31

 

Year ended December 31

 

($000s)

2025

 

2024

 

% Change

 

2025

 

2024

 

% Change

 

Net revenue

 

148,843

 

 

154,080

 

 

-3.4

%

 

539,632

 

 

555,259

 

 

-2.8

%

Gross profit

 

38,658

 

 

38,236

 

 

1.1

%

 

139,651

 

 

139,706

 

 

0.0

%

Gross margin

 

26.0

%

 

24.8

%

 

1.2

pp

 

25.9

%

 

25.2

%

 

0.7

pp

Operating income

 

12,240

 

 

12,325

 

 

-0.7

%

 

36,516

 

 

34,781

 

 

5.0

%

Adjusted operating income

 

12,240

 

 

12,325

 

 

-0.7

%

 

36,516

 

 

34,781

 

 

5.0

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  • Net revenue for Liquor Retail continued to decline in the fourth quarter of 2025, as market demand softness persisted and impacted same-store sales (2), which decreased by -4.0% in the fourth quarter and -2.3% for the full year. During the fourth quarter of 2025 two new Wine & Beyond stores were opened in Regina (SK) and Calgary (AB) as part of the plan to expand our successful W&B format. 

    (2)   Same-store sales is a specified financial measure that does not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures used by other companies. See “Non-IFRS Measures” section below for further information.

  • Operating Income remained virtually flat despite revenue declines, driven by pricing and mix management strategies that supported Gross Margin improvement, including the expansion of private label offerings at accretive margins, as well as cost optimization and in-store productivity initiatives.

Cannabis Retail

SNDL is one of Canada’s largest private-sector cannabis retailer, operating at March 11, 2026 in 192 locations under its three retail banners: “Value Buds” (127), “Spiritleaf” (60, of which 4 are corporate stores and 56 are franchise stores), and “Cost Cannabis” (5). The Company’s Cannabis Retail strategy is based on several pillars, including the quality of its store locations, its range of products, and the unique experiences provided to customers. Using data and insights from a large volume of monthly transactions enables SNDL to leverage technology and analytics to inform and improve its retail strategy.

 

Three months ended December 31

 

Year ended December 31

 

($000s)

2025

 

2024

 

% Change

 

2025

 

2024

 

% Change

 

Net revenue

 

83,282

 

 

83,170

 

 

0.1

%

 

330,242

 

 

311,689

 

 

6.0

%

Gross profit

 

22,079

 

 

20,490

 

 

7.8

%

 

86,053

 

 

78,827

 

 

9.2

%

Gross margin

 

26.5

%

 

24.6

%

 

1.9

pp

 

26.1

%

 

25.3

%

 

0.8

pp

Operating income

 

8,003

 

 

(8,997

)

 

189.0

%

 

30,332

 

 

(1,742

)

 

1841.2

%

Adjusted operating income

 

8,003

 

 

6,003

 

 

33.3

%

 

30,332

 

 

13,258

 

 

128.8

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  • Net revenue for Cannabis Retail reached a new full-year record as our Value Buds banner continued to gain market share. Same-store sales grew +3.9% for the full year, although declined by (0.7)% in the fourth quarter of 2025 driven by a market slow-down. Subsequent to year-end, the Company completed the acquisition and integration of five “Cost Cannabis” stores located in Alberta and Saskatchewan from 1CM.

  • Operating Income shows strong growth in both the fourth quarter of 2025 and full year, supported by continuous gross margin expansion, including the achievement of a new full-year record, and improved SG&A cost efficiencies. The year-on-year comparison is impacted by a $15 million Spiritleaf intangible asset impairment recorded in the fourth quarter of 2024, related to the conversion of several Spiritleaf stores to Value Buds. Adjusted Operating Income excludes this Spiritleaf intangible impairment and more clearly reflects the normalized improvement in the segment’s underlying operating profitability.

Cannabis Operations

SNDL has a diverse brand portfolio from value to premium, emphasizing premium inhalable formats and a full suite of 2.0 products. With enhanced procurement capabilities and plans to continue evolving toward a cost-effective cultivation and manufacturing operation, the Cannabis Operations segment is a key enabler of SNDL’s vertical integration strategy.

 

Three months ended December 31

 

Year ended December 31

 

($000s)

2025

 

2024

 

% Change

 

2025

 

2024

 

% Change

 

Net revenue

 

37,112

 

 

37,092

 

 

0.1

%

 

144,656

 

 

109,470

 

 

32.1

%

Gross profit

 

9,492

 

 

10,073

 

 

-5.8

%

 

32,944

 

 

21,798

 

 

51.1

%

Gross margin

 

25.6

%

 

27.2

%

 

-1.6

pp

 

22.8

%

 

19.9

%

 

2.9

pp

Operating income (loss)

 

1,874

 

 

4,391

 

 

-57.3

%

 

(1,754

)

 

2,663

 

 

-165.9

%

Adjusted operating income (loss)

 

2,154

 

 

4,439

 

 

-51.5

%

 

2,454

 

 

3,091

 

 

-20.6

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  • Cannabis Operations reported a new full-year Net Revenue record. This expansion is mainly driven by edibles, following Indiva’s acquisition in the fourth quarter of 2024, as well as international sales growing from $3.6 million in 2024 to $12.6 million in 2025.

  • While the segment achieved a new full-year Gross Margin record, results were impacted in the third quarter of 2025 by inventory write-offs and valuation adjustments related to the cultivation ramp-up, and the fixed-asset write-off of the idle Stellarton facility, as well as by restructuring charges related to the Indiva integration mostly during the first quarter of 2025.

Investments

  • As of December 31, 2025, the Company has deployed capital to a portfolio of cannabis-related investments with a carrying value of $397.6 million, including $385.5 million to SunStream Bancorp Inc. (“SunStream”). This carrying value was reduced by $5.6 million during the fourth quarter of 2025, primarily due to a decrease in the USD to CAD exchange rate from 1.3921 on September 30, 2025 to 1.3706 on December 31, 2025.

  • The previously disclosed restructuring process relating to Skymint continues. SNDL is awaiting an update from the Michigan Supreme Court expected in Q3 2026, which is expected to determine whether the court will accept the case for further review. Timing and outcomes remain uncertain and subject to court process and other factors.

  • The previously disclosed restructuring process relating to Parallel continues. On February 4, 2025, the Florida Department of Health approved the transfer of Parallel’s license, representing an important milestone in completing Parallel’s restructuring process. In December 2025, a settlement was reached resolving the final remaining litigation, and SNDL currently expects the strict foreclosure process to close in Q3 2026, subject to completion of remaining steps, satisfaction of applicable conditions, and any required approvals.

  • SunStream continues to hold exposure to The Cannabist Company Holdings Inc. (“Cannabist”) through the senior secured notes, with an aggregate position of approximately $35 million and estimated NAV of $28.3 million. Forecasted liquidity challenges have led Cannabist to pursue asset divestitures. Based on scenarios reviewed by Cannabist’s advisors, SNDL believes there is a pathway to full recovery of the senior secured notes relative to current NAV estimates, although outcomes remain subject to execution risk and other uncertainties.

  • The investment portfolio generated a positive operating income of $2.4 million in the fourth quarter of 2025 and $4.2 million in the full year, primarily driven by interests earned from our cash accounts.

  • On December 18, 2025, U.S. President Donald Trump issued an executive order directing the Department of Justice to expedite the process to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act. The order did not itself reclassify cannabis but instead directed regulators to finalize an ongoing rulemaking process. If finalized, while not constituting federal legalization, reclassification is expected to improve tax exposure for companies operating in the U.S. through the elimination of Section 280E, expand medical research and regulatory clarity, and incrementally enhance access to capital. These developments would meaningfully improve industry economics and investability.

Equity Position

  • $649.9 million of unrestricted cash, marketable securities and investments, including investments in equity-accounted investees, and no outstanding debt at December 31, 2025, resulting in a net book value of $1.1 billion.

  • The board of directors of the Company has approved the renewal of its Share Repurchase Program upon the expiry of its share repurchase program on November 20, 2025.

  • For the three months ended December 31, 2025, the Company purchased for cancellation 136,362 common shares at a weighted average price, excluding commissions, of US$1.64 per share. Subsequent to year-end, between January 1, 2026 and March 9, 2026 the Company purchased and cancelled an additional 4,153,358 common shares at a weighted average price, excluding commissions, of US$1.56 per share. SNDL will continue to evaluate opportunities to utilize the program to the extent that management believes it is in the best interest of SNDL’s shareholders. As a reminder, since the fourth quarter of 2024 the Company has repurchased 15,055,627 common shares for cancellation.

This press release is intended to be read in conjunction with the Company’s consolidated financial statements and the notes thereto for the years ended December 31, 2025 and 2024, and the accompanying Management’s Discussion and Analysis. These documents are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov/edgar.shtml.

CONFERENCE CALL  

The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Thursday, March 12, 2026.

WEBCAST ACCESS
To access the live webcast of the call, please visit the following link:
https://edge.media-server.com/mmc/p/aps8jm4e

REPLAY

A replay of the webcast will be available at https://sndl.com/financials/quarterly-results/default.aspx

ABOUT SNDL INC. 

SNDL Inc. (NASDAQ: SNDL, CSE: SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer in Canada, with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf and Cost Cannabis. With products available in licensed cannabis retail locations nationally, SNDL’s consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Grön, No Future and Bhang Chocolate. SNDL's investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry. For more information, please visit www.sndl.com

For more information: 
Tomas Bottger
SNDL Inc. 
O: 1.587.327.2017 
E: [email protected]

Forward-Looking Information Cautionary Statement  
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"), including, but not limited to, statements regarding the Company’s operational goals, plans and key priorities, the Company’s ability to deploy capital and the expected benefits thereof, the growth opportunities available to SNDL and the expected benefits thereof, expectations with respect to the 1CM transaction, including the satisfaction of certain regulatory approvals, the progress of the Sunstream restructurings, expectations with respect to the Skymint and Parallel restructuring processes, SNDL’s corporate restructuring program, including the timing to conclude the restructuring and expected benefits thereof, the expected benefits of the ERP consolidation, SNDL’s ability to recover the senior secured notes held in Cannabist, the potential impact of reclassifying cannabis from Schedule I to Schedule III under the Controlled Substances Act, the Company’s retail strategy, and any other potential forms of shareholder value creation. Forward-looking statements are frequently characterized by words such as “aim”, “anticipate”, “assume”, “believe”, “contemplate”, “continue”, “could”, “due”, “estimate”, “expect”, “goal”, “intend”, “may”, “objective”, “plan”, “predict”, “potential”, “positioned”, “pioneer”, “seek”, “should”, “target”, “will”, “would”, and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the Company’s business and the industry in which it operates and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond its control. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Please see “Risk Factors” in the Company’s Annual Information Form dated March 11, 2026, and the risk factors included in our other public disclosure documents for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

 

 

Condensed Consolidated Statement of Loss and Comprehensive Loss
(Expressed in thousands of Canadian dollars, except per share amounts)

 

 

 

 

 

 

 

Year ended
December 31

 

 

 

2025

 

 

2024

 

Net revenue

 

 

946,401

 

 

 

920,448

 

Cost of sales

 

 

687,753

 

 

 

680,117

 

Gross profit

 

 

258,648

 

 

 

240,331

 

 

 

 

 

 

 

 

Investment income

 

 

7,814

 

 

 

15,551

 

Share of loss of equity-accounted investees

 

 

(3,605

)

 

 

(65,459

)

 

 

 

 

 

 

 

General and administrative

 

 

182,162

 

 

 

187,243

 

Sales and marketing

 

 

14,565

 

 

 

12,004

 

Depreciation and amortization

 

 

51,948

 

 

 

54,250

 

Share-based compensation

 

 

13,905

 

 

 

20,037

 

Restructuring costs

 

 

3,337

 

 

 

2,667

 

Asset impairment, net

 

 

2,618

 

 

 

17,317

 

Research and development

 

 

489

 

 

 

346

 

Loss on disposition of assets

 

 

182

 

 

 

370

 

Operating loss

 

 

(6,349

)

 

 

(103,811

)

 

 

 

 

 

 

 

Other expenses, net

 

 

(9,425

)

 

 

(1,798

)

Loss before income tax

 

 

(15,774

)

 

 

(105,609

)

Income tax recovery

 

 

 

 

 

9,405

 

Net loss

 

 

(15,774

)

 

 

(96,204

)

 

 

 

 

 

 

 

Equity-accounted investees - share of other comprehensive (loss) income

 

 

(19,233

)

 

 

31,489

 

Investments at fair value through other comprehensive income ("FVOCI") - change in fair value

 

 

5,358

 

 

 

1,864

 

Comprehensive loss

 

 

(29,649

)

 

 

(62,851

)

 

 

 

 

 

 

 

Net loss attributable to:

 

 

 

 

 

 

Owners of the Company

 

 

(15,774

)

 

 

(94,796

)

Non-controlling interest

 

 

 

 

 

(1,408

)

 

 

 

(15,774

)

 

 

(96,204

)

Comprehensive loss attributable to:

 

 

 

 

 

 

Owners of the Company

 

 

(29,649

)

 

 

(61,443

)

Non-controlling interest

 

 

 

 

 

(1,408

)

 

 

 

(29,649

)

 

 

(62,851

)

Net loss per common share attributable to owners of the Company

 

 

 

 

 

 

Basic and diluted

 

$

(0.06

)

 

$

(0.36

)


 

 

 

 

 

Condensed Consolidated Statement of Financial Position
(Expressed in thousands of Canadian dollars)

 

 

 

 

 

 

As at

December 31, 2025

 

December 31, 2024

 

 

 

 

 

 

Assets

 

 

 

 

Current assets

 

 

 

 

Cash and cash equivalents

 

252,243

 

 

218,359

 

Restricted cash

 

20,081

 

 

19,815

 

Marketable securities

 

84

 

 

139

 

Accounts receivable

 

27,643

 

 

28,118

 

Biological assets

 

3,120

 

 

1,187

 

Inventory

 

126,877

 

 

127,919

 

Prepaid expenses and deposits

 

15,566

 

 

16,860

 

Investments

 

484

 

 

27,560

 

Assets held for sale

 

746

 

 

19,051

 

Net investment in subleases

 

2,775

 

 

2,832

 

 

 

449,619

 

 

461,840

 

Non-current assets

 

 

 

 

Long-term deposits and receivables

 

4,526

 

 

3,679

 

Right of use assets

 

138,353

 

 

115,435

 

Property, plant and equipment

 

151,900

 

 

145,810

 

Net investment in subleases

 

11,643

 

 

15,354

 

Intangible assets

 

58,520

 

 

61,325

 

Investments

 

11,574

 

 

8,427

 

Equity-accounted investees

 

385,534

 

 

413,124

 

Goodwill

 

124,248

 

 

124,248

 

Total assets

 

1,335,917

 

 

1,349,242

 

 

 

 

 

 

Liabilities

 

 

 

 

Current liabilities

 

 

 

 

Accounts payable and accrued liabilities

 

56,747

 

 

56,275

 

Lease liabilities

 

35,462

 

 

34,256

 

Derivative warrants

 

 

 

26

 

 

 

92,209

 

 

90,557

 

Non-current liabilities

 

 

 

 

Lease liabilities

 

134,471

 

 

118,017

 

Other liabilities

 

8,041

 

 

7,312

 

Total liabilities

 

234,721

 

 

215,886

 

 

 

 

 

 

Shareholders’ equity

 

 

 

 

Share capital

 

2,310,398

 

 

2,346,728

 

Warrants

 

306

 

 

667

 

Contributed surplus

 

54,038

 

 

57,156

 

Accumulated deficit

 

(1,302,441

)

 

(1,323,965

)

Accumulated other comprehensive income ("AOCI")

 

38,895

 

 

52,770

 

Total shareholders’ equity

 

1,101,196

 

 

1,133,356

 

Total liabilities and shareholders’ equity

 

1,335,917

 

 

1,349,242

 


 

 

Condensed Consolidated Statement of Cash Flows
(Expressed in thousands of Canadian dollars)

 

 

 

 

 

 

 

Year ended
December 31

 

 

 

2025

 

 

2024

 

Cash provided by (used in):

 

 

 

 

 

 

Operating activities

 

 

 

 

 

 

Net loss for the period

 

 

(15,774

)

 

 

(96,204

)

Adjustments for:

 

 

 

 

 

 

Income tax recovery

 

 

 

 

 

(9,405

)

Interest and fee income

 

 

(7,436

)

 

 

(15,637

)

Change in fair value of biological assets

 

 

(2,322

)

 

 

675

 

Change in fair value of inventory sold

 

 

1,252

 

 

 

(1,567

)

Share-based compensation

 

 

13,905

 

 

 

20,037

 

Depreciation and amortization

 

 

56,271

 

 

 

56,711

 

Loss on disposition of assets

 

 

182

 

 

 

370

 

Inventory impairment and obsolescence

 

 

2,671

 

 

 

3,707

 

Finance costs, net

 

 

6,693

 

 

 

7,161

 

Change in estimate of fair value of derivative warrants

 

 

(26

)

 

 

(4,374

)

Unrealized foreign exchange loss

 

 

614

 

 

 

108

 

Transaction costs

 

 

 

 

 

164

 

Bargain purchase gain

 

 

 

 

 

(5,456

)

Asset impairment, net

 

 

2,618

 

 

 

17,317

 

Share of loss of equity-accounted investees

 

 

3,605

 

 

 

65,459

 

Unrealized (gain) loss on marketable securities

 

 

(378

)

 

 

86

 

Additions to marketable securities

 

 

433

 

 

 

 

Income distributions from equity-accounted investees

 

 

68

 

 

 

10,715

 

Interest received

 

 

7,109

 

 

 

12,494

 

Change in non-cash working capital

 

 

1,432

 

 

 

(7,447

)

Net cash provided by operating activities

 

 

70,917

 

 

 

54,914

 

Investing activities

 

 

 

 

 

 

Additions to property, plant and equipment

 

 

(12,811

)

 

 

(8,615

)

Additions to intangible assets

 

 

 

 

 

(2,404

)

Additions to investments

 

 

(16,414

)

 

 

(36,155

)

Principal payments from investments

 

 

27,488

 

 

 

13,538

 

Proceeds from disposal of investments

 

 

18,090

 

 

 

 

Capital refunds from equity-accounted investees

 

 

 

 

 

168

 

Capital distributions from equity-accounted investees

 

 

4,684

 

 

 

89,758

 

Proceeds from disposal of property, plant and equipment

 

 

813

 

 

 

734

 

Acquisitions, net of cash acquired

 

 

(3,000

)

 

 

(39,644

)

Change in non-cash working capital

 

 

(1,396

)

 

 

383

 

Net cash provided by investing activities

 

 

17,454

 

 

 

17,763

 

Financing activities

 

 

 

 

 

 

Change in restricted cash

 

 

(267

)

 

 

76

 

Payments on lease liabilities, net

 

 

(39,245

)

 

 

(36,952

)

Repurchase of common shares

 

 

(15,348

)

 

 

(13,219

)

Proceeds from issuance of shares, net of costs

 

 

 

 

 

(59

)

Issuance of common shares by subsidiaries

 

 

 

 

 

174

 

Change in non-cash working capital

 

 

373

 

 

 

621

 

Net cash used in financing activities

 

 

(54,487

)

 

 

(49,359

)

Change in cash and cash equivalents

 

 

33,884

 

 

 

23,318

 

Cash and cash equivalents, beginning of period

 

 

218,359

 

 

 

195,041

 

Cash and cash equivalents, end of period

 

 

252,243

 

 

 

218,359

 


NON-IFRS MEASURES

Certain specified financial measures in this news release are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures reported by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for or superior to measures of performance prepared in accordance with IFRS. These measures are presented and described in order to provide shareholders and potential investors with additional measures in understanding the Company’s operating results in the same manner as the management team.

ADJUSTED OPERATING INCOME (LOSS)
Adjusted operating income (loss) is a non-IFRS financial measure which the Company uses to evaluate its operating performance in a similar manner to its management team. The Company defines adjusted operating income (loss) as operating income (loss) less restructuring costs (recovery), goodwill and intangible asset impairments and asset impairments triggered by restructuring activities.

The following tables reconcile adjusted to un-adjusted operating income (loss) for the periods noted.

($000s)

Cannabis
Retail

 

Cannabis
Operations

 

Cannabis
Total

 

Liquor
Retail

 

Investments

 

Corporate

 

Total

 

Three months ended December 31, 2025

 

Operating income (loss)

 

8,003

 

 

1,874

 

 

9,877

 

 

12,240

 

 

2,434

 

 

(12,800

)

 

11,751

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring costs

 

 

 

280

 

 

280

 

 

 

 

 

 

770

 

 

1,050

 

Impairments triggered by restructuring

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted operating income (loss)

 

8,003

 

 

2,154

 

 

10,157

 

 

12,240

 

 

2,434

 

 

(12,030

)

 

12,801

 


($000s)

Cannabis
Retail

 

Cannabis
Operations

 

Cannabis
Total

 

Liquor
Retail

 

Investments

 

Corporate

 

Total

 

Year ended December 31, 2025

 

Operating income (loss)

 

30,332

 

 

(1,754

)

 

28,578

 

 

36,516

 

 

4,209

 

 

(75,652

)

 

(6,349

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring costs

 

 

 

1,108

 

 

1,108

 

 

 

 

 

 

2,229

 

 

3,337

 

Impairments triggered by restructuring

 

 

 

3,100

 

 

3,100

 

 

 

 

 

 

 

 

3,100

 

Adjusted operating income (loss)

 

30,332

 

 

2,454

 

 

32,786

 

 

36,516

 

 

4,209

 

 

(73,423

)

 

88

 


($000s)

Cannabis
Retail

 

Cannabis
Operations

 

Cannabis
Total

 

Liquor
Retail

 

Investments

 

Corporate

 

Total

 

Three months ended December 31, 2024

 

Operating income (loss)

 

(8,997

)

 

4,391

 

 

(4,606

)

 

12,325

 

 

(63,724

)

 

(20,084

)

 

(76,089

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring costs (recovery)

 

 

 

48

 

 

48

 

 

 

 

 

 

569

 

 

617

 

Goodwill and intangible asset impairments

 

15,000

 

 

 

 

15,000

 

 

 

 

 

 

 

 

15,000

 

Adjusted operating income (loss)

 

6,003

 

 

4,439

 

 

10,442

 

 

12,325

 

 

(63,724

)

 

(19,515

)

 

(60,472

)


($000s)

Cannabis
Retail

 

Cannabis
Operations

 

Cannabis
Total

 

Liquor
Retail

 

Investments

 

Corporate

 

Total

 

Year ended December 31, 2024

 

Operating income (loss)

 

(1,742

)

 

2,663

 

 

921

 

 

34,781

 

 

(50,013

)

 

(89,500

)

 

(103,811

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring costs

 

 

 

428

 

 

428

 

 

 

 

 

 

2,239

 

 

2,667

 

Goodwill and intangible asset impairments

 

15,000

 

 

 

 

15,000

 

 

 

 

 

 

 

 

15,000

 

Adjusted operating income (loss)

 

13,258

 

 

3,091

 

 

16,349

 

 

34,781

 

 

(50,013

)

 

(87,261

)

 

(86,144

)


GROSS MARGIN
Gross margin is a supplementary financial measure calculated as gross profit divided by net revenue for the periods presented. This measure evaluates the underlying profitability of our operations and provides useful information about the Company’s ability to price products effectively, manage input costs, drive operating efficiencies, and compare results across periods and business segments

FREE CASH FLOW
Free cash flow is a non-IFRS financial measure which the Company uses to evaluate its financial performance, providing information which management believes to be useful in understanding and evaluating the Company’s ability to generate positive cash flows as it removes cash used for non-operational items. The Company defines free cash flow as the total change in cash and cash equivalents less cash used for common share repurchases, dividends (if any), changes to debt instruments, changes to long-term investments, net cash used for acquisitions plus cash provided by dispositions (if any).

The following table reconciles free cash flow to change in cash and cash equivalents for the periods noted.

 

 

Three months ended
December 31

 

 

Year ended
December 31

 

($000s)

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Change in cash and cash equivalents

 

 

11,662

 

 

 

(44,617

)

 

 

33,884

 

 

 

23,318

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

Repurchase of common shares

 

 

314

 

 

 

13,219

 

 

 

15,348

 

 

 

13,219

 

Changes to long-term investments

 

 

(3,758

)

 

 

5,033

 

 

 

(34,281

)

 

 

(67,309

)

Acquisitions, net of cash acquired

 

 

2,000

 

 

 

37,990

 

 

 

3,000

 

 

 

39,644

 

Free cash flow

 

 

10,218

 

 

 

11,625

 

 

 

17,951

 

 

 

8,872

 


SAME STORE SALES
Same store sales is a non-IFRS financial measure which the Company uses to evaluate its financial performance in its retail segments. Same store sales provides information which management believes to be useful to investors, analysts and others in understanding and evaluating the Company’s sales trends excluding the effect of the opening and closure of stores.

Same store sales refers to the revenue generated by the Company’s existing retail locations during the current and prior comparison periods.

ADJUSTED EBITDA
Adjusted EBITDA is a non-IFRS financial measure which the Company uses to evaluate its operating performance. Adjusted EBITDA provides information to investors, analysts, and others to aid in understanding and evaluating the Company’s operating results. The Company defines adjusted EBITDA as net earnings (loss) before inventory and biological assets fair value and impairment adjustments, share of (gain) loss of equity-accounted investees, depreciation and amortization, share-based compensation expense, restructuring costs, asset impairment, gain or loss on disposal of property, other expenses, net, income tax expense (recovery) and excluding non-recurring items including enterprise resource planning (“ERP”) implementation costs and litigation settlements, net of recoveries.

 

 

Three months ended
December 31

 

 

Year ended
December 31

 

($000s)

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Net earnings (loss)

 

 

9,367

 

 

 

(67,249

)

 

 

(15,774

)

 

 

(96,204

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

Inventory and biological assets fair value and impairment adjustments

 

 

184

 

 

 

(179

)

 

 

1,601

 

 

 

2,615

 

Share of (gain) loss of equity-accounted investees

 

 

(782

)

 

 

66,458

 

 

 

3,605

 

 

 

65,459

 

Depreciation and amortization

 

 

12,872

 

 

 

13,199

 

 

 

51,948

 

 

 

54,250

 

Share-based compensation

 

 

(1,285

)

 

 

4,609

 

 

 

13,905

 

 

 

20,037

 

Restructuring costs

 

 

1,050

 

 

 

617

 

 

 

3,337

 

 

 

2,667

 

Asset impairment

 

 

(353

)

 

 

15,000

 

 

 

2,618

 

 

 

17,317

 

Loss (gain) on disposition of PP&E

 

 

236

 

 

 

(71

)

 

 

182

 

 

 

370

 

Other expenses, net

 

 

2,384

 

 

 

(2,282

)

 

 

9,425

 

 

 

1,798

 

Income tax recovery

 

 

 

 

 

(6,558

)

 

 

 

 

 

(9,405

)

Non-recurring items

 

 

75

 

 

 

181

 

 

 

(621

)

 

 

882

 

Adjusted EBITDA

 

 

23,748

 

 

 

23,725

 

 

 

70,226

 

 

 

59,786

 



Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren